A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
NCT ID: NCT06837246
Last Updated: 2025-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
422 participants
INTERVENTIONAL
2025-02-24
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multivitamin for Health and Cognition
NCT07145658
Cognitive Vitality Pilot Study
NCT07208279
An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits
NCT05523115
Vitamin (VIT) for Vigilance Study
NCT05574530
Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood
NCT06384586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cognitive Nutritional Supplement
Intervention is pills of cognitive nutrient
Cognitive Nutritional Supplement
Pills of cognitive nutritional supplement
Placebo
Intervention is pills of matching placebo
Placebo
Matching placebo to active
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Nutritional Supplement
Pills of cognitive nutritional supplement
Placebo
Matching placebo to active
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. English is the primary spoken language.
3. Able to operate a study-provided iPad connected to the internet with a strong and reliable internet connection.
4. Willing to consume 3 capsules per day for 12 weeks.
5. Willing to review and follow all training materials provided.
6. Willing to avoid alcohol, marijuana/hemp products (including CBD products), and vigorous physical activity 24 h prior to the baseline (week 0), mid-point (Week 6), and end of study (Week 12) cognition testing days.
7. Non-user or former user (cessation ≥12 months of screening) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco, nicotine gums or lozenges) with no plans to begin use during the study period.
8. Willing to maintain habitual diet and physical activity patterns throughout the study.
9. Willing to refrain from exclusionary medications, supplements, and products throughout the study.
10. Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Principal Investigator.
Exclusion Criteria
1. Diagnosed neurological disorder such as Alzheimer's disease, Parkinson's disease, stroke, intracranial hemorrhage, or any brain lesions including tumors.
2. Diagnosed mental health disorder, such as major depressive disorder or any anxiety disorder. The use of daily or as-needed prescription medications to treat these conditions is also exclusionary.
3. Any infective or inflammatory brain disease, including those of viral, fungal, or syphilitic etiologies.
4. Elective hospitalizations planned (e.g., elective cosmetic procedures) during the study period.
5. Color blindness or visual impairments that cannot be corrected with glasses or contact lenses.
6. Diagnosed sleep disorder (e.g., sleep apnea) or occupation where sleep during the overnight hours is irregular (e.g., 3rd shift of overnight workers).
7. History of repeated head injury (e.g., concussions from sports activities) or single trauma resulting in a period of unconsciousness lasting 1 h or more.
8. Diagnosis of a learning and/or behavioral disorders such as dyslexia.
9. Diagnosis of attention-deficit/hyperactivity disorder (ADHD).
10. Use of any dietary supplements, other than a conventional once-daily multivitamin/mineral supplement that does not contain certain nutrient with cognitive effects, during the study period. Participants will be allowed to discontinue use of exclusionary dietary supplements during the screening period.
11. Experienced a major life stress event, including the death of a loved one, marriage or divorce, birth of a child, unemployment, or moved to a new residence, within the last 6 months.
General health related criteria
12. History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
13. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
General safety related criteria
14. Exposure to any non-registered drug product or has participated in another intervention study within 30 days prior to screening.
15. Recent history (within 12 months of visit 1) of alcohol or substance abuse. Alcohol abuse is defined as \>14 drinks per week (1 drink = 12 oz. beer, 5 oz. wine, or 1½ oz. distilled spirits).
16. Another household member is a current participant in this study.
17. Any condition the Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.
6.2.1 Excluded Products
* Tobacco / nicotine products within 12 months of screening and throughout the study period
* Any non-registered drug product within 30 days of screening
* Alcohol within 24 h of each cognition test day
* Marijuana/hemp products (including CBD products) within 24 h of each cognition test day
* Current use of any medication used to treat mental health disorders, such as major depressive disorder or any anxiety disorder
* Current use of any medications used to treat ADHD
* Current use of any dietary supplements, other than a conventional once-daily multivitamin/mineral supplement that does not contain certain nutrient with cognitive effect. Participants will be allowed to discontinue use of exclusionary dietary supplements during the screening period.
25 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmavite LLC
INDUSTRY
Balchem Corporation
INDUSTRY
Biofortis, Inc. (a Mérieux NutriSciences company)
UNKNOWN
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biofortis Innovation Services
Addison, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIO-2409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.